Supreme Court Asks India to Disclose Vaccine Trial Data
(Bloomberg) -- India's Supreme Court directed the government to disclose results and data on Covid vaccine trials and ruled that people can't be forced to take vaccines.
Disclosures must include reporting on adverse events, key findings of past trials and all data from future trials, a two-judge panel said Monday. It upheld the government's vaccination policy and grant of emergency-use approvals to vaccines.
India has administered 1.89 billion shots as on May 2, fully vaccinating 85% of its adult population. The South Asian nation recently allowed children older than five years to receive Covid shots.
“Every person taking vaccines should have access to data on the risks and benefits. It's the decent thing to do especially in a democracy,” said Jayaprakash Muliyil, an epidemiologist and member of a task force that advises the government on vaccines. Opacity in trial data and overemphasizing vaccines to prevent spread of infection resulted in vaccine hesitancy, he said.
Forcing people to be vaccinated is against their “bodily integrity” and the court “suggests” the government and private sector review curbs on unvaccinated individuals, the court said.
The government said no one is forced to take a vaccine and lawyers for vaccine makers Serum Institute of India and Bharat Biotech International Ltd. opposed the petition saying required data is already public.
©2022 Bloomberg L.P.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.